AUNA S.A. (AUNA) Form 6-K — Aug 18, 2026
Auna reported 2Q26 revenue of S/1,238 million, up 13% year-over-year on a reported basis and 9% FX-neutral, but Adjusted EBITDA fell 9% FXN to S/227 million with an 18.4% margin, as service mix, pharmacy and payroll costs, and accepted penalties tied to prior-year billing reconciliations in Peru pressured margins in Mexico, Peru and Colombia. Net income declined to S/33 million from S/84 million a year earlier (EPS of S/0.40 vs S/1.10), driven primarily by a S/61 million drop in non-cash FX gains within net finance costs; Adjusted Net Income was S/40 million versus S/89 million in 2Q25.
Key figures
- Eps
- S/0.40 basic and diluted (2Q26)
- Revenue
- S/1,238 million (2Q26; ~USD 363 million)
- Guidance
- FY26 revenue growth near ~12% midpoint of 10-14% FXN range; Adjusted EBITDA growth toward the low end of that range; CapEx ~4% of revenues; FCF expected to exceed original internal expectations
- Net Income
- S/33 million (vs S/84 million in 2Q25)
- Total Debt
- S/3,730 million gross debt (Jun 30, 2026)
- Revenue Yoy
- +13% reported / +9% FXN
- Total Assets
- S/7,796 million (Jun 30, 2026)
- Cash Position
- S/478 million (Jun 30, 2026)
- Net debt
- S/3,252 million
- Surgeries
- 21,912 (+5.2% YoY)
- Adjusted eps
- S/0.50
- Oncology mlr
- 50.1%
- Leverage ratio
- 3.6x (medium-term target <3.0x)
- Adjusted ebitda
- S/227 million (-9% FXN YoY, -6% reported; +3% FXN vs 1Q26)
- Net finance cost
- S/105 million (vs S/46 million in 2Q25)
- Days hospitalized
- 135,107 (+5% YoY)
- Free cash flow ytd
- S/400 million (+181% YoY vs S/143 million)
- Adjusted net income
- S/40 million (vs S/89 million in 2Q25)
- Weighted avg shares
- 74237368
- Adjusted ebitda margin
- 18.4%
- Operating cash flow ytd
- S/441 million net cash from operating activities; cash generated from operations +45% YoY
- Chemo radiotherapy sessions
- +15% YoY
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.